Literature DB >> 20007836

Alterations in the intraocular cytokine milieu after intravitreal bevacizumab.

Farzin Forooghian1, Peter J Kertes, Kenneth T Eng, Elvira Agrón, Emily Y Chew.   

Abstract

PURPOSE: Several complications after intravitreal bevacizumab (IVB) treatment have been described including tears of the retinal pigment epithelium and tractional retinal detachment. The etiology of these complications remains unclear. The purpose of this study was to characterize changes in the intraocular levels of inflammatory cytokines after IVB as a possible explanation for these complications.
METHODS: Twenty-nine patients with proliferative diabetic retinopathy (PDR) undergoing pars plana vitrectomy (PPV) for vitreous hemorrhage (VH) with IVB pretreatment were prospectively enrolled. Aqueous humor samples were taken at the time of IVB pretreatment and approximately 1 week later at the time of PPV. Multiplex cytokine arrays were used to assay 20 different cytokines. Multivariate general linear regression was performed to determine differences in cytokine levels between the two study visits. Proportional hazards regression was performed to determine the relationship between cytokine levels at PPV and postoperative outcomes.
RESULTS: After treatment with IVB, vascular endothelial growth factor (VEGF) concentrations in the aqueous humor decreased (P = 0.0003), whereas the concentrations of IL-8 and transforming growth factor (TGF)-beta(2) increased after IVB (P < 0.03). The level of IL-8 at the time of PPV was associated with the occurrence of recurrent VH after surgery (hazard ratio, 1.32; P = 0.02).
CONCLUSIONS: Alterations in the intraocular inflammatory cytokine milieu occur after IVB injection, possibly as a compensatory mechanism in response to VEGF inhibition. The increased concentrations of inflammatory cytokines after IVB may be clinically significant and may be responsible for some of the complications after IVB.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20007836      PMCID: PMC2868488          DOI: 10.1167/iovs.09-4065

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  51 in total

1.  Vitreous levels of placenta growth factor and vascular endothelial growth factor in patients with proliferative diabetic retinopathy.

Authors:  Yoshinori Mitamura; Asako Tashimo; Yasushi Nakamura; Hiroshi Tagawa; Kenji Ohtsuka; Yuka Mizue; Jun Nishihira
Journal:  Diabetes Care       Date:  2002-12       Impact factor: 19.112

2.  Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management.

Authors:  M Boulton; Z Gregor; D McLeod; D Charteris; J Jarvis-Evans; P Moriarty; A Khaliq; D Foreman; D Allamby; B Bardsley
Journal:  Br J Ophthalmol       Date:  1997-03       Impact factor: 4.638

3.  Increased expression of placenta growth factor in proliferative diabetic retinopathy.

Authors:  A Khaliq; D Foreman; A Ahmed; H Weich; Z Gregor; D McLeod; M Boulton
Journal:  Lab Invest       Date:  1998-01       Impact factor: 5.662

Review 4.  Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy.

Authors:  Harold F Dvorak
Journal:  J Clin Oncol       Date:  2002-11-01       Impact factor: 44.544

5.  Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy.

Authors:  A P Adamis; J W Miller; M T Bernal; D J D'Amico; J Folkman; T K Yeo; K T Yeo
Journal:  Am J Ophthalmol       Date:  1994-10-15       Impact factor: 5.258

Review 6.  Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown.

Authors:  A Pfeiffer; J Spranger; R Meyer-Schwickerath; H Schatz
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

7.  TGF-beta1, TGF-beta3, and PGE(2) regulate contraction of human patellar tendon fibroblasts.

Authors:  B H Campbell; C Agarwal; J H-C Wang
Journal:  Biomech Model Mechanobiol       Date:  2004-04-22

8.  Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy.

Authors:  S G Elner; V M Elner; G J Jaffe; A Stuart; S L Kunkel; R M Strieter
Journal:  Curr Eye Res       Date:  1995-11       Impact factor: 2.424

9.  Cytokines in human intraocular inflammation.

Authors:  W A Franks; G A Limb; M R Stanford; J Ogilvie; R A Wolstencroft; A H Chignell; D C Dumonde
Journal:  Curr Eye Res       Date:  1992       Impact factor: 2.424

10.  Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Authors:  L P Aiello; R L Avery; P G Arrigg; B A Keyt; H D Jampel; S T Shah; L R Pasquale; H Thieme; M A Iwamoto; J E Park
Journal:  N Engl J Med       Date:  1994-12-01       Impact factor: 91.245

View more
  28 in total

1.  Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis).

Authors:  Clement K Chan; Atul Jain; Srinivas Sadda; Neeta Varshney
Journal:  Trans Am Ophthalmol Soc       Date:  2014-07

2.  Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature.

Authors:  Jikui Shen; Maike Frye; Bonnie L Lee; Jessica L Reinardy; Joseph M McClung; Kun Ding; Masashi Kojima; Huiming Xia; Christopher Seidel; Raquel Lima e Silva; Aling Dong; Sean F Hackett; Jiangxia Wang; Brian W Howard; Dietmar Vestweber; Christopher D Kontos; Kevin G Peters; Peter A Campochiaro
Journal:  J Clin Invest       Date:  2014-09-02       Impact factor: 14.808

3.  Angiogenesis-related cytokines in serum of proliferative diabetic retinopathy patients before and after vitrectomy.

Authors:  Shuang Li; Xun-An Fu; Xiao-Fang Zhou; You-Yan Chen; Wei-Qun Chen
Journal:  Int J Ophthalmol       Date:  2012-12-18       Impact factor: 1.779

Review 4.  Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema.

Authors:  Peter A Campochiaro; Kevin G Peters
Journal:  Curr Diab Rep       Date:  2016-12       Impact factor: 4.810

5.  Validation of molecular and genomic biomarkers of retinal drug efficacy: use of ocular fluid sampling to evaluate VEGF.

Authors:  Rajesh K Sharma; Cheryl L Rowe-Rendleman
Journal:  Neurochem Res       Date:  2010-12-07       Impact factor: 3.996

6.  Angiofibrotic response to vascular endothelial growth factor inhibition in diabetic retinal detachment: report no. 1.

Authors:  Elliott H Sohn; Shikun He; Leo A Kim; Hani Salehi-Had; Michael Javaheri; Christine Spee; Laurie Dustin; David R Hinton; Dean Eliott
Journal:  Arch Ophthalmol       Date:  2012-09

7.  Protein Microarrays for Ocular Diseases.

Authors:  Guillermo Solís-Fernández; Ana Montero-Calle; Miren Alonso-Navarro; Miguel Ángel Fernandez-Torres; Victoria Eugenia Lledó; María Garranzo-Asensio; Rodrigo Barderas; Ana Guzman-Aranguez
Journal:  Methods Mol Biol       Date:  2021

8.  Increased intravitreous interleukin-18 correlated to vascular endothelial growth factor in patients with active proliferative diabetic retinopathy.

Authors:  Zongming Song; Min Sun; Fen Zhou; Fang Huang; Jia Qu; Ding Chen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-02-15       Impact factor: 3.117

9.  Cytokines associated with hemorrhage in proliferative diabetic retinopathy.

Authors:  Ho Ra; Anna Lee; Junhyuck Lee; Inkee Kim; Jiwon Baek
Journal:  Int Ophthalmol       Date:  2021-02-20       Impact factor: 2.031

10.  Vascular endothelial growth factor expression and inhibition in uveal melanoma cell lines.

Authors:  Patrick Logan; Julia Burnier; Miguel N Burnier
Journal:  Ecancermedicalscience       Date:  2013-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.